Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Röhricht, Frank ^a   Gadhia, Seema ^b   Alam, Rinku ^c   Willis, Melissa ^d  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b Buckinghamshire NHS Primary Care Trust Community Pharmacy   (United Kingdom)

^c NORTH EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; MELPERONE;

ADULT; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; MALE; MEDICAL AUDIT; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRESCRIPTION; QUALITY OF LIFE; SCHIZOPHRENIA; SYMPTOM; TREATMENT REFUSAL;

EID: 84871932621     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/512047     Document Type: Article

References (15)

1. Kerwin R. W., Bolonna A., Management of Clozapine-resistant schizophrenia Advances in Psychiatric Treatment 2005 11 2 101 106
2. Conley R. R., Buchanan R. W., Evaluation of treatment-resistant schizophrenia Schizophrenia Bulletin 1997 23 4 663 674
3. National Institute for Clinical Excellence, http://www.nice.org.uk
4. Kane J., Honigfeld G., Singer J., Meltzer H., Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with Chlorpromazine Archives of General Psychiatry 1988 45 9 789 796
5. Wahlbeck K., Cheine M., Essali A., Adams C., Evidence of Clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials American Journal of Psychiatry 1999 156 7 990 999
6. Sandoz. Summary of Product Characteristics
7. Wiesel F. A., Farde L., Halldin C., Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET Acta Psychiatrica Scandinavica, Supplement 1989 80 352 30 34
8. Bobo W. V., Jayathilake K., Lee M. A., Meltzer H. Y., Melperone, an atypical antipsychotic drug with Clozapine-like effect on plasma prolactin: contrast with typical neuroleptics Human Psychopharmacology 2009 24 5 415 422
9. Barbato L., Monge A., Stocchi F., Nordera G., Melperone in the treatment of iatrogenic psychosis in Parkinson's disease Functional Neurology 1996 11 4 201 207
10. Bobo W. V., Jayathilake K., Lee M. A., Meltzer H. Y., Changes in weight and body mass index during treatment with melperone, Clozapine and typical neuroleptics Psychiatry Research 2010 176 2-3 114 119
11. Stein S., Schmoldt A., Schulz M., Fatal intoxication with melperone Forensic Science International 2000 113 13 409 413
12. Bjerkenstedt L., Melperone in the treatment of schizophrenia Acta Psychiatrica Scandinavica, Supplement 1989 80 352 35 39
13. Meltzer H. Y., Sumiyoshi T., Jayathilake K., Melperone in the treatment of neuroleptic-resistant schizophrenia Psychiatry Research 2001 105 3 201 209
14. Ventura J., Lukoff D., Nuechterlein K. H., Appendix 1: Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0) scales, anchor points and administration manual International Journal of Methods in Psychiatric Research 1993 3 227 243
15. Sumiyoshi T., Jayathilake K., Meltzer H. Y., A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia Schizophrenia Research 2003 62 1-2 65 72